Evidence map›Paper›PMID 38765675›Full record

ArticleLaryngoscope investigative otolaryngology2024

N-acetylcysteine microparticles reduce cisplatin-induced RSC96 Schwann cell toxicity.

Katherine Kedeshian, Michelle Hong, Larry Hoffman, Ashley Kita

Abstract read
In one paragraph

Article in Laryngoscope investigative otolaryngology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Transtympanic Injection of Antioxidant-Eluting Microparticles for Otoprotection From Cisplatin Toxicity in a Mouse Model.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2025
    Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Katherine KedeshianDepartment of Head and Neck Surgery David Geffen School of Medicine at University of California Los Angeles Los Angeles California USA.ORCID https://orcid.org/0009-0009-3088-7283
Michelle HongDepartment of Head and Neck Surgery David Geffen School of Medicine at University of California Los Angeles Los Angeles California USA.ORCID https://orcid.org/0000-0002-1897-8635
Larry HoffmanDepartment of Head and Neck Surgery David Geffen School of Medicine at University of California Los Angeles Los Angeles California USA.
Ashley KitaDepartment of Head and Neck Surgery David Geffen School of Medicine at University of California Los Angeles Los Angeles California USA.ORCID https://orcid.org/0000-0002-2759-8271

Funding

Prolonged Local Melatonin Delivery for Recurrent Laryngeal Nerve NeuropraxiaK08DC019957 · NIDCD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Ashley Kita · 2022 to 2026
$1.1M
NIDCD NIH HHS K08 DC019957
6 · The paper itself

Abstract

Objectives: Cisplatin is known to cause inner ear dysfunction. There is growing evidence that cisplatin-induced demyelination of spiral or Scarpa's ganglion neurons may play an additional role in drug-induced ototoxicity alongside afferent neuron injury. As Schwann cells produce myelin, there may be an opportunity to reduce ototoxic inner ear damage by promoting Schwann cell viability. This work describes a cellular model of cisplatin-induced Schwann cell injury and investigates the ability of the antioxidant N-acetylcysteine to promote Schwann cell viability. A local delivery system of drug-eluting microparticles was then fabricated, characterized, and investigated for bioactivity. Methods: RSC96 rat Schwann cells were dosed with varying concentrations of cisplatin to obtain a dose curve and identify the lethal concentration of 50% of the cells (LC Results: The LC Conclusion: RSC96 Schwann cell injury following cisplatin insult is characterized in this in vitro model. Cisplatin caused injury at physiologic concentrations and N-acetylcysteine improved cell viability and mitigated this injury. N-acetylcysteine was packaged into microparticles and eluted N-acetylcysteine retained its ability to increase cell viability, thus demonstrating promise as a therapeutic to offset cisplatin-induced ototoxicity. Level of Evidence: N/A Laryngoscope, 2023.

Indexed as

cisplatinmicroparticleN‐acetylcysteineototoxicityRSC96

Identifiers

PMID38765675
PMCPMC11099882

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.